Macquarie Group’s Perspective Therapeutics CATX Stock Holding History

Macquarie Group’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,399	Closed	-$17	–	1940
2024 Q1	$17	Buy	+1,399	New	+$11.9K	﹤0.01%	1698

Other funds holding CATX

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Macquarie Group's CATX Position: Q2 2024 in Review

Macquarie Group sold out of Perspective Therapeutics (CATX) in Q2 2024, closing a stake of 1,399 shares — an estimated $17 sold.

Macquarie Group first reported a position in CATX in Q1 2024 and held it in 1 quarter. The position peaked at $17 in Q1 2024. 105 funds tracked by Wall St. Rank hold CATX as of Q2 2024.

Macquarie Group reported no remaining Perspective Therapeutics position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 1,399 Perspective Therapeutics shares in Q2 2024, an estimated $17.
Macquarie Group first reported a position in Perspective Therapeutics in Q1 2024 and held it in 1 quarter.
Macquarie Group's Perspective Therapeutics position peaked at $17 in Q1 2024.
105 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.